Price Target Changed • Jun 16
Price target decreased by 9.3% to €12.30 Down from €13.57, the current price target is an average from 3 analysts. New target price is 167% above last closing price of €4.60. Stock is down 22% over the past year. The company is forecast to post a net loss per share of €0.26 next year compared to a net loss per share of €0.23 last year. Ankündigung • May 11
Hyloris Pharmaceuticals SA, Annual General Meeting, Jun 09, 2026 Hyloris Pharmaceuticals SA, Annual General Meeting, Jun 09, 2026, at 14:00 Romance Standard Time. Ankündigung • Apr 23
Hyloris Pharmaceuticals SA to Report Fiscal Year 2026 Results on Mar 25, 2027 Hyloris Pharmaceuticals SA announced that they will report fiscal year 2026 results on Mar 25, 2027 Breakeven Date Change • Mar 26
Forecast breakeven date pushed back to 2028 The 3 analysts covering Hyloris Pharmaceuticals previously expected the company to break even in 2027. New consensus forecast suggests the company will make a profit of €89.7m in 2028. Average annual earnings growth of 66% is required to achieve expected profit on schedule. New Risk • Dec 31
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Belgian stocks, typically moving 7.1% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-€7.4m free cash flow). Share price has been highly volatile over the past 3 months (7.1% average weekly change). New Risk • Nov 17
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Belgian stocks, typically moving 4.8% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Less than 1 year of cash runway based on free cash flow trend (-€7.4m free cash flow). Minor Risk Share price has been volatile over the past 3 months (4.8% average weekly change). Major Estimate Revision • Oct 28
Consensus revenue estimates increase by 15% The consensus outlook for fiscal year 2025 has been updated. 2025 revenue forecast increased from €8.85m to €10.2m. EPS estimate unchanged from -€0.55 at last update. Pharmaceuticals industry in Belgium expected to see average net income growth of 24% next year. Consensus price target of €13.00 unchanged from last update. Share price rose 4.3% to €5.86 over the past week. Breakeven Date Change • Oct 27
Forecast breakeven date moved forward to 2026 The 2 analysts covering Hyloris Pharmaceuticals previously expected the company to break even in 2027. New consensus forecast suggests the company will make a profit of €2.80m in 2026. Average annual earnings growth of 124% is required to achieve expected profit on schedule. Reported Earnings • Sep 28
First half 2025 earnings released: €0.13 loss per share (vs €0.12 loss in 1H 2024) First half 2025 results: €0.13 loss per share (further deteriorated from €0.12 loss in 1H 2024). Revenue: €3.34m (down 28% from 1H 2024). Net loss: €3.56m (loss widened 2.0% from 1H 2024). Revenue is forecast to grow 89% p.a. on average during the next 3 years, compared to a 5.3% growth forecast for the Pharmaceuticals industry in Europe. Over the last 3 years on average, earnings per share has increased by 13% per year but the company’s share price has fallen by 23% per year, which means it is significantly lagging earnings. New Risk • Sep 25
New major risk - Financial position The company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -€7.4m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. This is currently the only risk that has been identified for the company. Board Change • Jul 18
Less than half of directors are independent Following the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 4 non-independent directors. Independent Director Melanie Mestdagt was the last independent director to join the board, commencing their role in 2025. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Breakeven Date Change • Jun 24
Forecast to breakeven in 2027 The 2 analysts covering Hyloris Pharmaceuticals expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of €13.6m in 2027. Average annual earnings growth of 60% is required to achieve expected profit on schedule. Ankündigung • May 13
Hyloris Pharmaceuticals SA, Annual General Meeting, Jun 10, 2025 Hyloris Pharmaceuticals SA, Annual General Meeting, Jun 10, 2025, at 14:00 Romance Standard Time. Breakeven Date Change • Feb 15
Forecast to breakeven in 2027 The 2 analysts covering Hyloris Pharmaceuticals expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of €44.5m in 2027. Average annual earnings growth of 41% is required to achieve expected profit on schedule. New Risk • Nov 18
New minor risk - Market cap size The company's market capitalization is less than US$100m. Market cap: €92.4m (US$97.3m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (11% average weekly change). Earnings are forecast to decline by an average of 14% per year for the foreseeable future. Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (€19m net loss in 2 years). Market cap is less than US$100m (€92.4m market cap, or US$97.3m). Reported Earnings • Oct 22
First half 2024 earnings released: €0.12 loss per share (vs €0.20 loss in 1H 2023) First half 2024 results: €0.12 loss per share (improved from €0.20 loss in 1H 2023). Revenue: €4.64m (up 143% from 1H 2023). Net loss: €3.49m (loss narrowed 38% from 1H 2023). Revenue is forecast to grow 68% p.a. on average during the next 3 years, compared to a 7.5% growth forecast for the Pharmaceuticals industry in Europe. Over the last 3 years on average, earnings per share has fallen by 8% per year but the company’s share price has fallen by 26% per year, which means it is performing significantly worse than earnings. Ankündigung • Oct 07
Hyloris Pharmaceuticals SA to Report Fiscal Year 2024 Results on Mar 20, 2025 Hyloris Pharmaceuticals SA announced that they will report fiscal year 2024 results on Mar 20, 2025 Ankündigung • Oct 05
Hyloris Pharmaceuticals SA to Report Fiscal Year 2024 Final Results on Apr 30, 2025 Hyloris Pharmaceuticals SA announced that they will report fiscal year 2024 final results at 9:00 AM, Central European Standard Time on Apr 30, 2025 New Risk • Sep 16
New major risk - Revenue and earnings growth Earnings are forecast to decline by an average of 3.5% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (24% average weekly change). Earnings are forecast to decline by an average of 3.5% per year for the foreseeable future. Minor Risks Latest financial reports are more than 6 months old (reported December 2023 fiscal period end). Currently unprofitable and not forecast to become profitable over next 3 years (€16m net loss in 3 years). Revenue is less than US$5m (€4.2m revenue, or US$4.7m). Breakeven Date Change • Sep 16
No longer forecast to breakeven The 2 analysts covering Hyloris Pharmaceuticals no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of €1.20m in 2026. New consensus forecast suggests the company will make a loss of €8.30m in 2026. New Risk • Aug 08
New major risk - Revenue and earnings growth Earnings are forecast to decline by an average of 4.2% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (16% average weekly change). Earnings are forecast to decline by an average of 4.2% per year for the foreseeable future. Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (€16m net loss in 3 years). Revenue is less than US$5m (€4.2m revenue, or US$4.6m). Breakeven Date Change • Aug 08
No longer forecast to breakeven The 2 analysts covering Hyloris Pharmaceuticals no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of €1.20m in 2026. New consensus forecast suggests the company will make a loss of €16.2m in 2026. Price Target Changed • Jul 09
Price target decreased by 7.5% to €19.10 Down from €20.65, the current price target is an average from 2 analysts. New target price is 63% above last closing price of €11.70. Stock is up 3.5% over the past year. Board Change • Jul 01
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 8 experienced directors. No highly experienced directors. Independent Director Chris Buyse was the last director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment. Major Estimate Revision • Apr 07
Consensus revenue estimates decrease by 14%, EPS upgraded The consensus outlook for fiscal year 2024 has been updated. 2024 revenue forecast fell from €9.45m to €8.15m. EPS estimate increased from -€0.525 to -€0.50 per share. Pharmaceuticals industry in Belgium expected to see average net income growth of 24% next year. Consensus price target up from €20.65 to €21.55. Share price rose 6.1% to €12.15 over the past week. Price Target Changed • Apr 05
Price target increased by 8.3% to €21.55 Up from €19.90, the current price target is an average from 2 analysts. New target price is 85% above last closing price of €11.65. Stock is down 11% over the past year. Major Estimate Revision • Mar 28
Consensus revenue estimates decrease by 50% The consensus outlook for fiscal year 2024 has been updated. 2024 revenue forecast fell from €24.3m to €12.2m. EPS estimate unchanged from -€0.53 per share at last update. Pharmaceuticals industry in Belgium expected to see average net income growth of 21% next year. Consensus price target up from €19.90 to €20.65. Share price was steady at €11.05 over the past week. Price Target Changed • Mar 27
Price target increased by 7.3% to €20.65 Up from €19.25, the current price target is an average from 2 analysts. New target price is 86% above last closing price of €11.10. Stock is down 13% over the past year. Ankündigung • Mar 21
Hyloris Pharmaceuticals SA to Report First Half, 2024 Results on Sep 05, 2024 Hyloris Pharmaceuticals SA announced that they will report first half, 2024 results on Sep 05, 2024 Reported Earnings • Mar 14
Full year 2023 earnings released Full year 2023 results: Net loss: €15.8m (loss widened 46% from FY 2022). Revenue is forecast to grow 47% p.a. on average during the next 3 years, compared to a 7.7% growth forecast for the Pharmaceuticals industry in Europe. Ankündigung • Feb 15
Hyloris Pharmaceuticals SA Enrolls First Patient in Phase 3 Clinical Trial for Its Proprietary Mouth Rinse to Control Incidences of Bleeding Related to Dental Procedures Hyloris Pharmaceuticals SA announced that the first patient has been enrolled in a pivotal Phase 3 clinical trial for Tranexamic Acid Oral Rinse. Hyloris' product candidate is a new treatment for use in patients on anti-coagulant therapies (blood thinners) undergoing dental procedures with a risk of excessive bleeding. It is an oral solution containing the locally-acting antifibrinolytic agent tranexamic acid. Positive data in a Phase 1 pharmacokinetic (PK) trial in healthy subjects suggested the treatment was well tolerated under varied conditions with no serious adverse events following tooth extraction, while effectively controlling procedural bleeding without delaying clot formation. Hyloris' proprietary reformulated oral rinse was developed for use in minor surgical procedures with complications/bleedings. The formulation can be used by dental care professionals for patients on anti-coagULant therapies who benefit from the opportunity to continue their anti-coagulant treatments when scheduled for dental procedures. By addressing the unique challenges faced by individuals on blood thinners, this oral care solution seeks to enhance the overall dental experience and improve the oral health of these patients. Tranexamic acid is an antifibrinolytic agents that has been used for decades to reduce or prevent postoperative bleeding in patients with bleeding problems. The drug is currently approved for intravenous administration (CYKLOKAPRON®? IV) in the U.S. for reduction or prevention of bleeding in patients having a high risk of intra and post-operative haemorrhage (during general and oral surgery, such as tooth extractions) due to a bleeding disorder such as haemophilia (as indicated). The drug is also approved in the U.S. as an oral tablet (LYSTEDA®?) for cyclic heavy menstrual bleeding. Ankündigung • Jan 30
Hyloris Pharmaceuticals SA Announces Positive Results for the Phase 2 Trial of Miconazole Domiphen-Bromide (MCZ-DB) in Patients with Acute Vulvovaginal Candidiasis Hyloris Pharmaceuticals SA announced positive results for the phase 2 trial of Miconazole Domiphen-Bromide (MCZ-DB) in patients with acute vulvovaginal candidiasis. The phase 2 trial of MCZ-DB was a 12-week, randomized, double-blind, active-controlled, dose finding trial evaluating the safety and efficacy of two doses of MCZ-DB (MCZ 2% combined with 0.14% or 0.29% of DB) administered once per day for 7 days in patients with acute vulvovaginal candidiasis. The study has been conducted in Belgium with a total of 102 patients enrolled. Efficacy was evaluated by assessing the clinical outcome and mycological outcome to the treatment. A positive clinical outcome is a resolution of VVC signs and symptoms whereas the mycological outcome is determined by a vaginal swab indicating the absence of Candida species yeast. Top line results are summarized: At day 29, day 57 and day 85, the low dose (MCZ and 0.14% of DB) demonstrated superior efficacy compared to the active control (MCZ). At day 15, both doses administered demonstrated positive safety and tolerability without significant superiority over the active control. MCZ-DB was well tolerated in both dose cohorts, with no reported serious adverse events. Following the treatments, there was no indication of systemic exposure to Domiphen Bromide. New Risk • Oct 25
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Belgian stocks, typically moving 4.5% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (4.5% average weekly change). Shareholders have been diluted in the past year (4.5% increase in shares outstanding). Revenue is less than US$5m (€3.1m revenue, or US$3.3m). Breakeven Date Change • Oct 25
Forecast breakeven date moved forward to 2024 The 2 analysts covering Hyloris Pharmaceuticals previously expected the company to break even in 2025. New consensus forecast suggests losses will reduce by 13% to 2023. The company is expected to make a profit of €1.05m in 2024. Average annual earnings growth of 116% is required to achieve expected profit on schedule. Ankündigung • Oct 18
Hyloris Pharmaceuticals SA Announces U.S. FDA Approval of Maxigesic® IV Hyloris Pharmaceuticals SA announced Maxigesic® IV has been approved for the relief of mild to moderate pain and for the management of moderate to severe pain as an adjunct to opioid analgesics in adults, where an intravenous route of administration is considered clinically necessary. The approval for the New Drug Application (NDA) is based on positive data from a Phase 3 program in which Maxigesic® IV demonstrated that it was well tolerated and offered faster onset of action and higher pain relief compared to Paracetamol IV (Acetaminophen IV) and Ibuprofen IV, as well as placebo. The superior analgesic effect of Maxigesic® IV was also supported by a range of secondary endpoints, including reduced opioid usage rates. An exclusive license and distribution agreement for the U.S., was already signed between Hyloris’ partner AFT Pharmaceuticals (“AFT”) and Hikma Pharmaceuticals (“Hikma”). Under the terms of the development collaboration agreement between Hyloris and AFT, Hyloris is eligible to receive a share on any product-related revenues, such as license fees, royalties and milestone payments, received by AFT. Distribution of Maxigesic® IV in U.S. hospitals should start in early 2024. Following first U.S. sales, Hyloris will be entitled to a milestone payment of USD 2,1 million. In addition, the payment of USD 1,5 million (approximately EUR 1,4 million) relating to existing trade receivables is expected. development of chronic opioid use after surgery is one of the most common post-operative complications2 with particularly devastating consequences. In the U.S., prevalence of new chronic opioid use after surgical procedures was estimated close to 6%3. In the past 2 decades, prescription opioid usage in the U.S. contributed to over 600,000 deaths related to opioid overdoses, with the annual death toll rising tenfold between 1999 and 2021 (80,000 deaths in 2021). Nearly 17,000 deaths involved prescription opioids in 20214.Patients requiring medical attention related to opioid abuse account for around $11 billion of added costs to the U.S. healthcare system annually, or 1% of all hospital costs5. Major Estimate Revision • Sep 13
Consensus revenue estimates increase by 28%, EPS downgraded The consensus outlook for fiscal year 2023 has been updated. 2023 revenue forecast increased from €9.80m to €12.5m. EPS estimate fell from -€0.47 to -€0.60 per share. Pharmaceuticals industry in Belgium expected to see average net income growth of 16% next year. Consensus price target broadly unchanged at €19.25. Share price was steady at €11.40 over the past week. New Risk • Sep 07
New major risk - Revenue and earnings growth Earnings are forecast to decline by an average of 1.3% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings are forecast to decline by an average of 1.3% per year for the foreseeable future. Minor Risks Currently unprofitable and not forecast to become profitable next year (€13m net loss next year). Shareholders have been diluted in the past year (4.5% increase in shares outstanding). Revenue is less than US$5m (€3.1m revenue, or US$3.3m). Price Target Changed • Jul 26
Price target decreased by 7.1% to €19.50 Down from €21.00, the current price target is provided by 1 analyst. New target price is 76% above last closing price of €11.10. Stock is down 23% over the past year. The company is forecast to post a net loss per share of €0.47 next year compared to a net loss per share of €0.40 last year. Breakeven Date Change • Jul 26
Forecast breakeven date pushed back to 2025 The analyst covering Hyloris Pharmaceuticals previously expected the company to break even in 2024. New forecast suggests losses will reduce by 9.6% per year to 2024. The company is expected to make a profit of €8.00m in 2025. Average annual earnings growth of 61% is required to achieve expected profit on schedule. New Risk • Jun 13
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Belgian stocks, typically moving 4.9% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (4.9% average weekly change). Shareholders have been diluted in the past year (4.5% increase in shares outstanding). Revenue is less than US$5m (€3.0m revenue, or US$3.2m). Reported Earnings • Mar 16
Full year 2022 earnings released Full year 2022 results: Net loss: €10.8m (loss narrowed 7.0% from FY 2021). Revenue is forecast to grow 83% p.a. on average during the next 3 years, compared to a 5.6% growth forecast for the Pharmaceuticals industry in Europe. Ankündigung • Jan 20
Hyloris Pharmaceuticals SA Expands Its Pipeline with A Product Candidate for A Mineral Deficiency in the Blood (Hypophosphatemia) Hyloris Pharmaceuticals SA announced it has in-licensed a product candidate targeting hypophosphatemia. This serious condition causes patients to have a low level of phosphorous in the blood. While mild hypophosphatemia is common and many patients are asymptomatic, severe hypophosphatemia can be life-threatening and requires medical treatment. The condition can result in different health challenges, including muscle and bone weakness, respiratory or heart failure, seizures or coma. Deficiency of this vital mineral is always linked to an underlying condition, such as diabetes, anorexia, use of diuretics or alcohol abuse. About Hypophosphatemia: Treatment protocols for patients deficient in phosphate are well-established and have proven useful in other situations of bone mineral imbalance. Oral administration is the preferred way of treating hypophosphatemia, although in most countries no approved drugs exist. Currently, physicians mostly rely on compounded drugs which have, by definition, not been submitted for regulatory scrutiny regarding safety, efficacy, and quality. The company will seek advice and approval from regulators by making use of the rich body of clinical data that has emerged from established clinical practice. With a primary on safety of the product, the company intends to conduct a streamlined development program to achieve market access in Europe, targeting regulatory approval in European countries as from 2026. Global rights of the ongoing development have been licensed-in from Dutch company, QliniQ, who maintains the rights to commercialize the product candidate in its home country, and a selected number of Middle Eastern and developing countries. Price Target Changed • Nov 16
Price target increased to €21.00 Up from €18.75, the current price target is provided by 1 analyst. New target price is 51% above last closing price of €13.92. Stock is down 9.3% over the past year. The company posted a net loss per share of €0.45 last year. Major Estimate Revision • Sep 02
Consensus forecasts updated The consensus outlook for 2022 has been updated. 2022 revenue forecast increased from €10.0m to €14.5m. EPS estimate unchanged from -€0.28 at last update. Pharmaceuticals industry in Belgium expected to see average net income growth of 4.4% next year. Consensus price target of €20.25 unchanged from last update. Share price was steady at €13.74 over the past week. Ankündigung • Sep 01
Hyloris Pharmaceuticals SA to Report Fiscal Year 2022 Results on Mar 16, 2023 Hyloris Pharmaceuticals SA announced that they will report fiscal year 2022 results on Mar 16, 2023 Major Estimate Revision • May 05
Consensus forecasts updated The consensus outlook for 2022 has been updated. 2022 expected loss increased from -€0.27 to -€0.41 per share. Revenue forecast of €14.5m unchanged since last update. Pharmaceuticals industry in Belgium expected to see average net income growth of 7.1% next year. Consensus price target of €20.25 unchanged from last update. Share price was steady at €16.50 over the past week. Breakeven Date Change • May 04
Forecast to breakeven in 2024 The 2 analysts covering Hyloris Pharmaceuticals expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of €7.00m in 2024. Average annual earnings growth of 72% is required to achieve expected profit on schedule. Price Target Changed • Apr 01
Price target increased to €19.50 Up from €17.75, the current price target is an average from 2 analysts. New target price is 22% above last closing price of €16.04. Stock is up 30% over the past year. The company is forecast to post a net loss per share of €0.27 next year compared to a net loss per share of €0.45 last year. Reported Earnings • Mar 17
Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind Full year 2021 results: €0.45 loss per share (down from €0.33 loss in FY 2020). Net loss: €11.6m (loss widened 62% from FY 2020). Revenue exceeded analyst estimates by 17%. Earnings per share (EPS) missed analyst estimates by 15%. Over the next year, revenue is forecast to grow 247%, compared to a 7.6% growth forecast for the pharmaceuticals industry in Belgium. Price Target Changed • Feb 25
Price target increased to €18.75 Up from €17.25, the current price target is an average from 2 analysts. New target price is 23% above last closing price of €15.30. Stock is up 31% over the past year. The company is forecast to post a net loss per share of €0.53 next year compared to a net loss per share of €0.33 last year. Breakeven Date Change • Jan 01
Forecast to breakeven in 2024 The 2 analysts covering Hyloris Pharmaceuticals expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of €7.00m in 2024. Average annual earnings growth of 56% is required to achieve expected profit on schedule. Price Target Changed • Dec 17
Price target increased to €17.75 Up from €16.50, the current price target is an average from 2 analysts. New target price is 5.0% above last closing price of €16.90. Stock is up 74% over the past year. The company is forecast to post a net loss per share of €0.53 next year compared to a net loss per share of €0.33 last year. Reported Earnings • Aug 05
First half 2021 earnings released: €0.32 loss per share (vs €0.21 loss in 1H 2020) First half 2021 results: Net loss: €8.24m (loss widened 120% from 1H 2020). Breakeven Date Change • May 20
Forecast to breakeven in 2024 The 2 analysts covering Hyloris Pharmaceuticals expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of €16.0m in 2024. Average annual earnings growth of 55% is required to achieve expected profit on schedule. Reported Earnings • Mar 12
Full year 2020 earnings released: €0.33 loss per share (vs €0.37 loss in FY 2019) Full year 2020 results: Net loss: €7.15m (loss widened 33% from FY 2019). Post-clinical trial products Approved (during full year): 1 Launched (during full year): 1 Analyst Estimate Surprise Post Earnings • Mar 12
Revenue and earnings miss expectations Revenue missed analyst estimates by 82%. Earnings per share (EPS) also missed analyst estimates by 81%. Over the next year, revenue is forecast to grow 1,843%, compared to a 6.3% growth forecast for the Pharmaceuticals industry in Belgium. Is New 90 Day High Low • Jan 07
New 90-day high: €11.90 The company is up 17% from its price of €10.14 on 09 October 2020. The Belgian market is up 11% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is down 7.0% over the same period.